Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
756 stopped studies mapped to Acute Leukemia and descendants · 89% state a reason
Over the 756 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03588936 | Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant | Phase 1 | terminated | Jul 17, 2018 | Medical College of Wisconsin | Poor accrual and loss of funding. | Enrollment / accrual |
| NCT04464889 | HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem… | Phase 1 | withdrawn | Jul 9, 2020 | Medigene AG | Medigene transfered all rights to a new Sponsor | Other (stated, no rule matched) |
| NCT02298166 | Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or… | Phase 3 | terminated | Nov 21, 2014 | University of Ulm | The manufacturer Arog Pharmaceuticals Inc has terminated the Agreement Concerning the Support of an… | Drug supply |
| NCT03473457 | CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia(AML) | N/A | terminated | Mar 22, 2018 | Zhujiang Hospital | The therapeutic effect was not as expected | Other (stated, no rule matched) |
| NCT01439347 | A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With… | Phase 3 | terminated | Sep 23, 2011 | Spectrum Pharmaceuticals, Inc | Sponsor decision | Sponsor / business decision |
| NCT03742323 | REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | terminated | Nov 15, 2018 | PETHEMA Foundation | Because of low recruitment | Enrollment / accrual |
| NCT02105116 | AML Therapy With Irradiated Allogeneic Cells | N/A | terminated | Apr 7, 2014 | Rutgers, The State University of New Jersey | No patients were eligible to receive the experimental component of the protocol therapy. | Other (stated, no rule matched) |
| NCT02229266 | Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy…(HINKL) | Phase 2 | terminated | Sep 1, 2014 | Technische Universität Dresden | low recruitment rate | Enrollment / accrual |
| NCT01113502 | Eltrombopag in Elderly Acute Myelogenous Leukemia (AML) | Phase 1 / Phase 2 | terminated | Apr 30, 2010 | Abramson Cancer Center at Penn Medicine | not stated | Not stated |
| NCT04296214 | Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic… | — | withdrawn | Mar 5, 2020 | Grupo Cooperativo de Hemopatías Malignas | Poor recruitment | Enrollment / accrual |
| NCT02440568 | AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in… | Phase 1 / Phase 2 | terminated | May 12, 2015 | University of Illinois at Chicago | not stated | Not stated |
| NCT03602898 | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate… | Phase 2 | withdrawn | Jul 27, 2018 | Fred Hutchinson Cancer Center | Insufficient funding | Funding |
| NCT01486784 | A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute… | Phase 1 / Phase 2 | terminated | Dec 7, 2011 | Abramson Cancer Center at Penn Medicine | not stated | Not stated |
| NCT03806192 | Feasibility of Partners in Care Program for Caregivers of Patients With Acute Myeloid… | N/A | terminated | Jan 16, 2019 | University of Washington | Terminated due to insufficient funding | Funding |
| NCT00914628 | Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients…(TK008) | Phase 3 | terminated | Jun 5, 2009 | AGC Biologics S.p.A. | EMA withdrew the marketing Authorisation at the request of AGC Biologics S.p.A (formerly MolMed… | Other (stated, no rule matched) |
| NCT04395092 | Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and… | Phase 2 | withdrawn | May 20, 2020 | Kiadis Pharma | The sponsor decided to withdraw this study | Sponsor / business decision |
| NCT00967343 | Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host… | Phase 2 / Phase 3 | terminated | Aug 27, 2009 | Kiadis Pharma | not stated | Not stated |
| NCT03579888 | CD19-Specific T Cells Post AlloSCT | Phase 1 | terminated | Jul 9, 2018 | M.D. Anderson Cancer Center | Study halted prematurely | Other (stated, no rule matched) |
| NCT02669264 | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute… | Phase 1 | terminated | Feb 1, 2016 | ADC Therapeutics S.A. | The study was early terminated prior to part 2 because of slow accrual. | Enrollment / accrual |
| NCT03066466 | Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD… | Phase 3 | withdrawn | Feb 28, 2017 | Loyola University | No participants were enrolled | Enrollment / accrual |
| NCT01599429 | Study of the Predictive Marker FLT in Patients Suffering From AML(TEP-FLT-LMA) | — | withdrawn | May 16, 2012 | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | No participants enrolled | Enrollment / accrual |
| NCT01685411 | Busulfan and Cyclophosphamide Followed By ALLO BMT | N/A | terminated | Sep 14, 2012 | Masonic Cancer Center, University of Minnesota | not stated | Not stated |
| NCT03094611 | Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive… | Phase 2 | terminated | Mar 29, 2017 | M.D. Anderson Cancer Center | the study was closed early due to competing trials | Other (stated, no rule matched) |
| NCT03125876 | A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML) | Phase 1 | terminated | Apr 24, 2017 | Sunshine Lake Pharma Co., Ltd. | Company strategy adjustment | Sponsor / business decision |
| NCT03360006 | A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With… | Phase 1 | terminated | Dec 2, 2017 | AbbVie | Strategic Reasons | Sponsor / business decision |
| NCT02648932 | The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With… | Phase 2 | terminated | Jan 7, 2016 | University of Chicago | Poor accrual | Enrollment / accrual |
| NCT00439296 | ABT-751 With Chemotherapy for Relapsed Pediatric ALL | Phase 1 / Phase 2 | terminated | Feb 23, 2007 | Therapeutic Advances in Childhood Leukemia Consortium | The study was stopped due to poor accrual and lack of funding. | Enrollment / accrual |
| NCT03113071 | Safety and Activity of Digoxin With Decitabine in Adult AML and MDS | Phase 1 / Phase 2 | terminated | Apr 13, 2017 | Fox Chase Cancer Center | Slow accrual | Enrollment / accrual |
| NCT03881735 | Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With… | Phase 2 | withdrawn | Mar 19, 2019 | Roswell Park Cancer Institute | no accrual | Enrollment / accrual |
| NCT03515707 | Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal… | Phase 2 | withdrawn | May 3, 2018 | Fred Hutchinson Cancer Center | PI recommended closure | Other (stated, no rule matched) |
| NCT00176930 | Stem Cell Transplant for Hematological Malignancy | N/A | terminated | Sep 15, 2005 | Masonic Cancer Center, University of Minnesota | replaced by another study ; Trial re-written as MT2015-29 | Other (stated, no rule matched) |
| NCT00615784 | Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia(UPCC04407) | Phase 2 | terminated | Feb 14, 2008 | Abramson Cancer Center at Penn Medicine | Study terminated. Eisai's Targretin acquired by another pharmaceutical company. | Sponsor / business decision |
| NCT03739606 | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer | Phase 2 | withdrawn | Nov 14, 2018 | City of Hope Medical Center | RSS recommendation | Other (stated, no rule matched) |
| NCT03709576 | Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell… | Phase 2 | terminated | Oct 17, 2018 | Milton S. Hershey Medical Center | Funding pulled | Funding |
| NCT01300611 | TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation(USBTXA127CBT) | Phase 1 | terminated | Feb 21, 2011 | Tarix Pharmaceuticals | not stated | Not stated |
| NCT04493099 | Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or… | Phase 1 / Phase 2 | withdrawn | Jul 30, 2020 | M.D. Anderson Cancer Center | The original sponsor was acquired by a new company and has elected to end funding for all… | Investigator |
| NCT04094766 | Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R… | Phase 1 | withdrawn | Sep 19, 2019 | Second Affiliated Hospital of Xi'an Jiaotong University | Production plan adjustment | Other (stated, no rule matched) |
| NCT01656252 | Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission(PrE0901) | Phase 1 / Phase 2 | terminated | Aug 2, 2012 | PrECOG, LLC. | Study stopped per Novartis request due to futility from another study. | Efficacy / futility |
| NCT01483690 | A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL | Phase 1 / Phase 2 | terminated | Dec 1, 2011 | Therapeutic Advances in Childhood Leukemia Consortium | Toxicity | Safety / toxicity |
| NCT02953561 | Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid… | Phase 1 / Phase 2 | terminated | Nov 2, 2016 | M.D. Anderson Cancer Center | PDOL request | Other (stated, no rule matched) |
| NCT02750254 | Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation | Phase 1 | terminated | Apr 25, 2016 | Washington University School of Medicine | Toxicity. Only enrolled patients in phase I portion of trial. | Safety / toxicity |
| NCT03963024 | Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT(TrRaMM-TMI) | Phase 1 | terminated | May 24, 2019 | IRCCS San Raffaele | low rate of enrolment | Enrollment / accrual |
| NCT04128020 | Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation… | Phase 1 | withdrawn | Oct 16, 2019 | Sherif Farag | Funder withdrew funding after not accruing any subjects after 1 year. | Enrollment / accrual |
| NCT00981799 | Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL | Phase 1 / Phase 2 | terminated | Sep 22, 2009 | Therapeutic Advances in Childhood Leukemia Consortium | Slow accrual rate | Enrollment / accrual |
| NCT02991898 | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | Phase 2 | terminated | Dec 14, 2016 | Masonic Cancer Center, University of Minnesota | Considering new technology for product. | Other (stated, no rule matched) |
| NCT03888534 | Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute… | Phase 1 | withdrawn | Mar 25, 2019 | Millennium Pharmaceuticals, Inc. | Business decision (no safety or efficacy concerns) | Safety / toxicity |
| NCT01658007 | Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute…(SIR-MO-1101) | Early Phase 1 | terminated | Aug 6, 2012 | Children's Hospital Medical Center, Cincinnati | Slow Accrual | Enrollment / accrual |
| NCT03985215 | The Value of Follow-Up After Childhood Acute Lymphoblastic Leukaemia in Denmark - Family… | — | withdrawn | Jun 13, 2019 | University of Aarhus | Overlapping with another danish questionnaire study | Other (stated, no rule matched) |
| NCT03515200 | Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic… | Phase 1 | terminated | May 3, 2018 | St. Jude Children's Research Hospital | Due to departure of PI from St. Jude | Other (stated, no rule matched) |
| NCT02767934 | Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic… | Phase 2 | terminated | May 11, 2016 | University of Washington | Terminated due to lack of efficacy | Efficacy / futility |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Oct 11, 2021source: clinicaltrials